Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

Sponsor
University Hospital of Crete
Study ID
NCT00754351
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
  • Docetaxel — DRUG
    Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
  • Gemcitabine — DRUG
    Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles

Study Details

This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 negative breast cancer.

Key Dates

First listed
Sep 18, 2008
Start date
Sep 30, 2008
Status verified
Jun 2012
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Bevacizumab-\>Docetaxel-\>Gemcitabine

Primary Outcome Measure

Overall response rate [ Time Frame: up to 6 months ]

Related Studies